At WORLDSymposium, Astellas Pharma presented interim safety data from a Phase I/II study assessing the company’s AAV gene therapy for the rare, autosomal metabolic disease Pompe disease.

Cambridge, Mass.-based Voyager Therapeutics entered a deal allowing Pfizer to exercise options to license novel capsids for gene therapies.

Dyno Therapeutics announced a licensing and collaboration deal with Roche worth up to $1.8 billion to apply the Cambridge, Mass.-based company’s CapsidMap platform to the development of adeno-associated virus (AAV) vectors for gene therapies for central nervous system diseases and liver-directed therapies.

Cambridge, Massachusetts-based Dyno Therapeutics came out of stealth mode with an official launch of the company’s proprietary CapsidMap platform.